Ketamine acts as an NMDA receptor antagonist, modulating glutamatergic neurotransmission and potentially reducing aberrant cortical hyperexcitability associated with Visual Snow Syndrome. By blocking glutamate receptors and influencing neuroplasticity, ketamine may help ameliorate visual processing abnormalities and potentially disrupt pathological neural circuit patterns underlying the syndrome's symptoms.